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LYMPHEDEMA HRQOL ASSESSMENTS
Abstract
In collaboration with Heidi Shaffer, one of the occupational therapists on staff at the MultiCare
lymphedema clinic in Gig Harbor, Washington, we sought to answer the question “Which patient-reported
outcome assessments are most valid and reliable in measuring health-related quality of life (HRQoL) in
patients with lymphedema?” We conducted a systematic literature review to answer this question. In
reviewing selected databases, 19 articles were chosen to appraise the evidence supporting psychometric
properties and clinical utility of 10 HRQoL assessments used for patients with lymphedema. The Disability of
the Arm, Shoulder and Hand (DASH) and Lymphedema Life Impact Scale (LLIS) assessments demonstrated
stronger evidence for test-retest reliability, internal consistency, and clinical utility for use in a lymphedema
practice setting in the U.S. than other assessments.
The next step was to bring the findings back to Heidi and her colleagues to answer questions they
had about using recommended assessments to generate G-codes for Medicare reporting and to explore
strategies that could be used to implement these recommended assessments within MultiCare’s electronic
medical record (EMR) system. We provided an in-service on our findings for MultiCare’s lymphedema
therapists, at which time we distributed laminated calculation cards for converting DASH scores to G-code
modifiers and obtained feedback through a satisfaction survey. In addition, we met with the Director of
Physical Medicine and Rehabilitation at MultiCare, Sherri Olsen, to determine the best process for
embedding the LLIS and the DASH into their EMR and identify future research needs. Additional steps will
include follow up on the progress and outcomes of embedding the assessments into the EMR and further
research to address changes in the literature, HRQoL assessments for other diagnostic populations, and
determining the efficacy and benefits of prehab treatments.
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Executive Summary
This year-long review effort began by asking the question, “Which functional outcome measures
used by lymphedema therapists are best for determining G-codes?” In order to meet the needs of our
collaborating clinician, Heidi Shaffer from the MultiCare lymphedema clinic in Gig Harbor, our research
question was changed to, “Which patient-reported outcome assessments are most valid and reliable in
measuring health-related quality of life in patients with lymphedema?” Currently, HRQoL measures specific
to patients with lymphedema are lacking psychometric rigor. These instruments are particularly critical
following a recent mandate by Medicare to produce G-codes, which report function-related outcomes. Our
aim with this literature review was to provide local lymphedema therapists with recommended HRQoL
assessments that could be used within the facility’s electronic medical record (EMR) system to generate
Medicare G-codes.
We conducted a systematic literature review to appraise the evidence supporting the psychometric
properties and clinical utility of 10 HRQoL assessments used for patients with lymphedema. To determine
which assessments to include in our review, we first identified HRQoL assessments commonly used in
lymphedema research. Next, we reviewed selected databases and chose 19 articles that met our inclusion
criteria (i.e. the study was peer-reviewed, analyzed one or more of the selected assessments) and exclusion
criteria (i.e. published prior to 1980, study population did not include patients with cancer and/or
lymphedema, and not available in English). Each article was categorized using American Occupational
Therapy Association (AOTA) levels of evidence and the research pyramid. All articles were considered and
reviewed by five individuals for inclusion in this review.
After critically appraising the articles, we determined that the DASH and the LLIS assessments
demonstrated the strongest evidence for test-retest reliability, internal consistency, and clinical utility for use
in a lymphedema practice setting in the U.S. We concluded there was strong evidence to recommend the
DASH and modest evidence to recommend the LLIS for use with patients with lymphedema. Specifically,
this review supports the use of the DASH for patients with lymphedema when lymphedema is secondary to
breast cancer. For patients with lymphedema not secondary to breast cancer, the LLIS was found to be the
most appropriate assessment at this time. Practitioners should evaluate the characteristics of each assessment
against a client's specific presentation (e.g. comorbidities, upper limb versus lower limb, etc.) to select the
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most appropriate assessment tool. Use of psychometrically sound assessments arms practitioners with
objective data to quantify function and progress of treatment. This demonstrates the effects of intervention to
third-party payers for purposes of reimbursement. In addition, such assessments provide cohesion across
therapists and settings and communicate intervention outcomes with a variety of disciplines along the
continuum of care.
To translate our findings into clinical practice, we conducted an in-service presentation to MultiCare
lymphedema therapists in Tacoma, WA., at which time we distributed laminated calculation cards for
converting DASH scores to G-code modifiers. At the conclusion of our presentation, we obtained feedback
through a satisfaction survey. Based on results from the survey, we concluded that we adequately informed
clinicians about psychometric properties of lymphedema HRQoL assessments. We also concluded that some
clinicians did not find the G-code modifier card useful, and that they were unlikely to begin using the DASH
if they were not already. In addition, we met with the Director of Physical Medicine and Rehabilitation at
MultiCare, Sherri Olsen, to determine the best process for embedding the LLIS and the DASH into their
EMR system. Next steps will include follow up on the progress and outcomes of embedding the assessments
into their EMR. Future research is needed to address changes in the literature, to identify HRQoL assessments
for other diagnostic populations, and to determine the efficacy and benefits of prehab treatments.

4

LYMPHEDEMA HRQOL ASSESSMENTS
Focused Question:
Which patient-reported outcome assessments are most valid and reliable in measuring health-related
quality of life (HRQoL) in patients with lymphedema?
Collaborating Occupational Therapy Practitioner:
Heidi Shaffer, OTR/L, CLT
Prepared By:
Bonnie Blair, OTS; Gina Dellino, OTS; Jennifer Thomas, OTS
Chair:
Tatiana Kaminsky, PhD, OTR/L
Course Mentor:
George Tomlin, PhD, OTR/L, FAOTA
Date Review Completed:
May 9, 2017
Clinical Scenario:
At the MultiCare lymphedema clinic in Gig Harbor, Washington, occupational therapists work with
patients to manage lymphedema: a chronic but manageable condition caused by the buildup of lymph
fluid when the lymphatic system is damaged or blocked (Bulley, Gaal, Coutts, Blyth, Jack, Chetty …
Tan, 2013). The majority of patients are referred from oncology seeking treatment for lymphedema
consequent to their cancer treatment. Typically, the goal of therapy is to manage lymphedema through
manual drainage, care for damaged skin, and compression garments and bandages for an improved
HRQoL (Bulley et al., 2013). In 2013, therapists were required to report functional outcomes via G-codes
for patients insured by Medicare part B (Doucet, 2013). For patients with lymphedema, HRQoL is an
important indicator of function (Morgan, Franks, & Moffatt, 2005). There is a lack of HRQoL measures
specific to patients with lymphedema that have psychometric rigor (Mitchell, Gleeson, DiCecco,
2008). Instruments that have completed psychometric testing are important for validating, guiding, and
improving the quality of intervention. In addition, these instruments are particularly critical to
occupational therapists during a time of increased demands by third party payers to produce functionrelated outcomes, an integral pillar of occupational therapy practice (Doucet, 2014). Currently, the
MultiCare lymphedema clinic is transitioning to using the Lymphedema Life Impact Scale to better
understand and report on functional outcomes of treatment.
This critically appraised topic will help to establish the most reliable and valid HRQoL measures to be
used for patients with lymphedema by reporting on existing instruments and their psychometric
properties. This information will serve the collaborating therapist in selecting the most appropriate
outcome measure for clinical use. The therapists at the Multicare lymphedema clinic in Gig Harbor wish
to know which HRQoL assessments are most reliable and valid to meet the demands of third party payers
and the requirements for G-code reporting set forth by Medicare.
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Review Process
Procedures for the selection and appraisal of articles
Inclusion Criteria:
Articles were chosen if:
 The study examined at least one of the ten HRQoL assessments and derivatives used with the
lymphedema population: LLIS, ULL-27, Lymph-ICF, LYMQOL, LyQLI, SF-36, EORTC QLQBR23, FACT-B+4, FLIC, or DASH and provided psychometric data.
 The study was peer-reviewed.
Exclusion Criteria:
Articles were excluded if:
 The study was published prior to 1980.
 The study population did not include any patients with cancer and/or lymphedema.
 The study is not available in English.

Search Strategy
Categories

Key Search Terms

Patient/Client
Population

Lymphedema, Breast Cancer

Intervention
(Assessment)

LLIS (Lymphedema Life Impact Scale), ULL-27, Lymph-ICF, LYMQOL
(Lymphedema Quality of Life), LyQLI (Lymphedema Quality of Life
Inventory), SF-36 Health Survey, NHP (Nottingham Health Profile), EORTC
QLQ-C30 (EORTC QCQ-BR23), FACT-B, FLIC (Functional Living IndexCancer), or DASH (Disability Arm Shoulder Hand)
Quality of Life, Functional Outcome Measures

Comparison
Outcomes

Psychometrics: reliability and validity
Development
Investigation
Evaluation

Databases and Sites Searched
AJOT, BJOT, CJOT
CINAHL
ProQuest
Research Gate (Publications)
Cochrane
MEDLINE
OT Seeker, OT Search
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Google Scholar
PubMed
References of References
Citation Tracking

Quality Control/Review Process:
Our initial search began by asking the question, “Which functional outcome measures used by
lymphedema therapists are best for determining G-codes?” After briefly reviewing the literature and in
consult with our chairperson and professors, we decided to eliminate G-codes from our research question
and focus on outcome components of lymphedema treatment. Since lymphedema is a chronic condition,
one of the main goals of treatment is improved quality of life. As such, our research question was
changed to, “Which patient-reported outcome assessments are most valid and reliable in measuring
health-related quality of life in patients with lymphedema?”
Based on this question, we generated a list of specific HRQoL assessments that are currently used by
lymphedema therapists. We then looked to see if psychometric studies had been completed and if the
assessment was feasible within the United States; we eliminated all measures that failed to meet these
criteria. Finally, we generated a list of key terms that included common diagnoses seen in this patient
population and terms directly from the clinical question to guide our search.

Results of Search
Table 1. Search Strategy of databases.
Search Terms

Date

Database

Initial
Hits

Articles
Excluded

Total Selected for
Review

Functional outcome measures
AND lymphedema

9/22/2016

CINAHL

1

0

1

Functional outcome measures
AND lymphedema

10/9/2016

ProQuest

1558

19

1

Functional outcome measures
AND lymphedema

10/09/2016

Cochrane

14

14

0
Not relevant or did
not meet inclusion
criteria.

Functional outcome measures
AND lymphedema

10/09/2016

MEDLINE

0

0

0

Functional outcome measures
AND lymphedema

10/09/2016

OT Search

0

0

0

Functional outcome measures
AND lymphedema

10/09/2016

OT Seeker

0

0

0

Functional outcome measures
AND lymphedema

10/09/2016

Google Scholar

10,700

20

0
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Functional outcome measures
AND lymphedema AND
psychometrics

10/09/2016

Google
Scholar

1,150

26

1

“Lymphedema functional
outcome measure
psychometrics”

10/09/2016

Google Scholar

0

0

0

Lymphedema functional
outcome measure psychometrics

10/09/2016

Google Scholar

1,200

35

0

Lymphedema AND reliability

10/15/2016

AJOT

6

6

0
Irrelevant

Lymphedema Life Impact Scale

10/18/2016

CINAHL

0

0

0

Lymphedema Quality of Life
Inventory (LyQLI)-Development
and investigation of validity and
reliability

10/18/2016

Primo

2

2

0

Lymphedema Life Impact Scale

10/18/2016

Cochrane

5

5

0

Nottingham Health Profile

10/18/2016

CINAHL

259

39

1
Irrelevant

Nottingham Health Profile AND
breast cancer

10/18/2016

CINAHL

2

2

0

EORTC AND reliability

10/18/2016

CINAHL

70

70

0

EORTC AND lymphedema

10/18/2016

CINAHL

5

5

0

Lymph-ICF AND reliability

10/18/2016

Primo

4

2

1
Duplicates

Lymph-ICF

10/18/2016

CINAHL

2

2

0
Duplicates

Lymph-ICF

10/18/2016

PubMed

5

5

0
Irrelevant or
duplicates

ULL-27 AND reliability

10/18/2016

PubMed

0

0

0

ULL-27 AND validity

10/18/2016

PubMed

1

1

0
Duplicates

ULL-27

10/18/2016

PubMed

2

2

0

Lymphedema AND reliability

10/18/2016

CINAHL

41

41

0
Duplicates

Lymphedema, quality of life

10/21/2016

Primo

573

52

0
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Lymphedema, quality of life
inventory

10/21/2016

Primo

237

43

0

Lymphedema life impact scale

10/21/2016

Google Scholar

9, 920

19

1

Lymphedema, quality of life,
validity, reliability

10/21/2016

PubMed

15

14

1

LBCQ AND lymphedema

10/21/2016

PubMed

8

8

0

LBCQ AND lymphedema

10/21/2016

ProQuest

17

17

0
(1 used for
background)

LBCQ AND reliability

10/21/2016

CINAHL

1

1

0

LBCQ AND validity

10/21/2016

CINAHL

2

0

0
(2 used for
background)

LBCQ and lymphedema

10/21/2016

Research Gate
(publications)

9

9

0

(FACT-B) AND reliability

10/21/2016

PubMed

20

20

0
(1 used for
reference tracking)

LYMQOL

10/21/2016

PubMed

1

1

0

Lymphedema quality of life
questionnaire

10/21/2016

CINAHL

2

2

0

Lymphedema quality of life
(LYMQOL)

10/21/2016

Google Scholar

71

70

1
Irrelevant or
duplicates

Psychometric AND
Lymphedema

10/21/2016

CINAHL

6

6

0

Psychometric evaluation of the
SF-36 health survey

10/22/2016

PubMed

2

2

2

SF-36 AND lymphedema AND
validity

10/22/2016

CINAHL

5

5

0

Nottingham Health Profile,
validity, reliability

10/22/2016

Primo

145

50

0

Functional living index cancer
AND validity

10/22/2016

PubMed

113

20

0

disability arm shoulder hand
AND validity

10/22/2016

PubMed

179

40

0

DASH AND psychometrics

10/22/2016

PubMed

91

20

0
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Lymphedema AND reliability

10/22/2016

BJOT

177

40

0
Duplicates or
Irrelevant

Lymphedema AND reliability

10/22/2016

CJOT

1

1

0
Irrelevant

Total number of articles used in review from database searches = 8
Table 2. Articles from citation tracking.
Article

Date

Database

Initial
Hits

Articles
Excluded

Total Selected for
Review

Davies, Ryans, Levenhage &
Perdomo (2014)

9/22/2016

ProQuest

17

16

1

Total number of articles used in review from citation tracking = 1
Table 3. Articles from reference tracking.
From Article

Date

Articles
Referenced

Articles
Excluded

Total Selected for
Review

Davies, Ryans, Levenhage &
Perdomo (2014)

10/18/2016

31

27

4

Wilson, R. W., Hutson, L. M. &
VanStry, D. (2005)

10/18/2016

37

36

1

Maratia, S., Cedillo, S. & Rejas, J.
(2016)

10/21/2016

62

57

5

Total number of articles used in review from reference tracking = 10
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CAT Table 4: Descriptive Studies
Author,
Year,
Journal
Abbreviatio
n
Brady,
Cella, Mo,
Bonomi,
Tulsky,
Lloyd,
Deasy,
Cobleigh,
Shiomoto
(1997), JCO

Study
Objectives

Study
Design/
Level of
Evidence

Validation of
the FACT-B

AOTA
level: IV
Pyramid
level: D2

Assessmen
ts or
screens
being
compared
FACT-B
FACT-G

Population/ Setting

Psychometrics

Summary of
results

Limitations

Cronbach’s α:
0.63-0.90

PSR

N = 47

FACT-B is
appropriate for use
in oncology clinical
trials and clinical
practice.
Demonstrates ease
of use, brevity,
reliability, validity,
and sensitivity to
change.

Must be administered
in its entirety; no
limitations listed or
found in the study
design.

FLIC

First sample:
Patients w/ advanced
BC, completed FACT-B
version 1, treated at
Rush-Presbyterian-St.
Luke’s Medical Center.
Patients tested twice
over 2 months.

BCSubscale

Second sample:
Adults w/ BC, w/o brain
metastasis, not using
psychotropic drugs, and
completed version 3 of
the FACT-B; recruited
from 3 medical centers
N = 295

Test-retest reliability:
Correlation coefficients:
0.88 for BC-Subscale,
0.89 for TOI-PFB, &
0.85 for FACT-B total
score, indicating high
degree of stability (3 to 7
days)
Validity:
The first sample
demonstrated sensitivity
to change on the total
score, the PWB subscale,
FWB subscale, and the
BC-Subscale with (F
(df=12,78) = 2.59: p
=0.006)
Construct validity:
FLIC (r=0.87; p <
0.001), FACT-G total
score (r=0.86; p <
0.001), TOI-PFB
(r=0.86; p < 0.001), and
BC-Subscale (r=0.53; p
< 0.001) for first sample.
Known-groups
validity:
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Coster,
Poole, &
Fallowfield
(2001),
BCRT

Document the
validation of
the FACT-B
w/ the
addition of
the 4-item
arm subscale
and the
sensitivity to
effects of arm
morbidity.

Prospective
longitudina
l
correlation
study
AOTA
level: IV
Pyramid
level: D2

FACT-B+4
FACT-B

Group 1
Population/Setting:
Participants in phase 1 of
the ALMANAC study,
under the care of breast
cancer surgeons in the
UK.
N: 279
Group 2
Population/Setting:
Women with known
chronic arm morbidity
attending a
lymphoedema clinic.
N: 29

F(18, 784) =10.27; p <
0.001
Cronbach’s α:
0.62 for BC subscale,
0.88 for total FACT-B+4
score, 0.83 for arm
subscale.
Test-Retest reliability:
Total arm subscale
(r=0.93), FACT-B+4
(r=0.97) over 5-day
period for group 2.
Group 2 scored lower on
all QoL subscales,
except EWB, than a
subset of group 1.
Non-parametric chisquared:
On all arm items was
significant, p=0.001,
89.36-13.47, df=4)
between the 2 groups.
Sensitivity to change
over time:
Was significantly lower
4 weeks post baseline
(prior to surgery)
measures for mean
scores (p=0.001), arm
subscales increased
significantly from
baseline measures
(p=0.01).

FACT-B+4 appears
to be
psychometrically
sound. It is suitable
to be used in
longitudinal surgical
trials. Reliability is
comparable to
previous validation
studies. Good testretest reliability.
There is reliable
discrimination
between patients w/
and w/o severe arm
morbidity. Arm
subscale and FACTB+4 were sensitive
to changes in arm
condition over time.
Patients found the
scale easy to
complete.

Study failed to
identify limitations of
the design, including
patients recruited
instead of randomly
selected. Study only
looked at change
over 12 weeks. Not
necessarily
generalizable to men.
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Davies,
Brockopp,
& Moe
(2015), RO

Devoogdt,
Groef,
Hendrickx,
Damstra,
Christiaanse
n,
Geraerts…
Kampen,
(2014),
PT

Determine
the
psychometric
s, including
test-retest and
internal
consistency
for using the
DASH with
BC survivors
with 2°
lymphedema.

Retrospecti
ve
Correlation
al Study

Develop the
Lymph-ICFLL (phase 1)
and to
determine the
reliability and
validity of the
Lymph-ICFLL (phase 2)

Correlation
al study

DASH

AOTA
level: IV
Pyramid
level: D2

Population: Women
diagnosed with BC, with
secondary lymphedema.
Mean age of 60yo
Setting: Outpatient
rehabilitation department
of a Magnet redesignated community
hospital.

Cronbach’s α:
Initial evaluation=0.97,
30-day reevaluation=0.92,
discharge=0.92
Test-retest:
ICC=0.97

The DASH is found
to have strong testretest reliability and
internal consistency
for measuring upper
extremity function
among BC survivors
with lymphedema.

Clients’ recall of
previous answers on
the assessment may
have affected testretest outcomes. First
study to look at this
demographic with the
DASH.
Not necessarily
generalizable to men
with lymphedema.

The Lymph-ICF-LL
has strong face,
construct, and
content validity. It
has strong reliability
with high intra-class
correlation
coefficients.
Developers provide
suggestions for
improving 4
questions that rated
moderate for testretest reliability via
administration.

Only tested Dutch
version of measure.
Phase 1 participant
diagnoses differed
from those of phase
2. Responsiveness of
the Lymph-ICF-LL
and known-groups
validity was not
tested for.

N:163

AOTA
level: IV
Pyramid
level: D2

LymphICF-LL
Compared
to:
SF-36
FLQA-I

Phase 1
Population:
Men (20%) & women
(80%) averaging 58.7
yo. who spoke Dutch
Diagnosed w/ 2° LE
lymphedema
Setting:
Leuven Lymphoedema
Center (Belgium)
N= 20
Phase 2

Reliability
Test-retest: 0.69-0.94
(correlation coefficient)
Internal Consistency:
0.82-0.97 (Cronbach α)
Measurement
Variability: acceptable;
SEM = 5.9 - 12.6
Validity
Content: good; questions
understandable (93% of
participants),
questionnaire
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Population:
Men (20%) & women
(80%) averaging 51 yo.
and spoke Dutch
Diagnosed w/ 1° or 2°
LE lymphedema
Setting:
Lymphedema clinic at
Nij Smellinghe Hospital
(Netherlands) (n= 11),
Leuven Lymphedema
Center (Belgium) (n= 19

comprehensive (90% of
participants)
Construct: good; all
hypotheses for
convergent and divergent
validity accepted
(correlation coefficients
for convergent validity
ranged from -0.46 to
-0.86 and divergent
validity ranged from
0.04 to -0.32).

(24/28 questions
very strong –
strong).

Reliability
Test-retest:
r =0.65 -0.93
Internal Consistency:
> 0.77 (Cronbach’s α)
Measurement
Variability:
acceptable;
SEM = 4.8-12.5

The final version of
the Lymph-ICF is a
reliable and valid
Dutch questionnaire
to assess functional
problems (as
defined by the
WHO-ICF) for
patients with
lymphedema 2° to
axillary dissection.

N= 30

Devoogdt,
Kampen,
Geraerts,
Coremans,
&
Christiaens
(2011), PT

Investigate
the reliability
and validity
of data
collected by
the final
version of the
Lymph-ICF

Correlation
al study
AOTA
level: IV,
Pyramid
level : D2

LymphICF
Compared
to SF-36

Population: Women w/
BC having undergone
unilateral axillary
dissection <12 months
prior to study. Dutch
speaking.
Setting:
Department of
Physiotherapy of the
University Hospital,
Leuven
N= 90 (n= 60 w/
lymphedema, n=30 w/o
lymphedema)

Validity
Content: good; questions
understandable, clear
scoring system for 88%
of participants,
lymphedema complaints

Study did not
investigate
responsiveness.
Focus on Dutch
version, limits
generalizability to the
USA. Lack of detail
for participant
characteristics in
phase 1 and use of
researcher developed
questionnaire to
determine content
validity introduces
bias and perhaps
confounding
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mentioned by 85% of
participants
Construct: good;
convergent validity
confirmed by 5 domains
on Lymph-ICF
correlating strongest w/
5 expected domains of
SF-36; divergent
confirmed 3/5
hypotheses accepted.
Keeley,
Crooks,
Locke,
Veigas,
Riches
Hilliam,
(2010), JL

Describe the
validation of
a conditionspecific QoL
measure for
lymphedema
of the limbs.

Retrospecti
ve
correlation
al study
AOTA
level: IV
Pyramid
level: D2

LYMQOL
Compared
to:
EORTC
QLQ-C30

New patients presenting
to the clinic.
Mean age: 58 years (SD
16.4 years).
78% were women,
bilateral leg swelling
was the most frequently
reported (43.8%), 26.8%
reported unilateral am
swelling, 27.7%
unilateral leg swelling,
1.5% reporting
combination of arm and
leg swelling

Face validity:
Was confirmed with
questionnaire, content
validity established via
phenomenological
interview of 22 patients

variables (within
participant
characteristics).
Participants may
have had trouble
distinguishing
between
complications due to
lymphedema versus
BC treatment.
Women only.
LYMQOL is a
validated QoL
assessment for use
w/ people w/ limb
lymphoedema

Limitations not
listed, full
psychometric data
findings from
previous 2004 study
not listed

The LyQLI shows
promise for clinical
settings and future
studies for those
with lymphedema.
Shown to have very
good internal
consistency
reliability.
Concurrent validity
was shown through

No patient expert
group evaluated in
final questionnaire.
Percentage of
missing items for the
patients ranged from
0 to 14.6%, mean
scores were used
instead. Patients
instructed not to
receive additional

Correlation coefficient:
for arm ranged from
0.689-0.937 and for leg
from 0.644-0.788
respectively w/
comparable domains in
the EOC QLQ-C30.

N = 209
Klernäs,
Johnsson,
Horstmann,
Kristjanson,
& Johansson
(2015), QLR

Reduce the
SLQOLI
from 188
items to 45
items to
create the
LyQLI.
Determine
psychometric
s of the
LyQLI,

Correlation
al Study
AOTA
level: IV
Pyramid
level: D2

LyQLI
Adapted
from
SLQOLI
Compared
against SF36

Population/Setting:
Outpatients from the
registers of the
lymphedema units at
Skane University
Hospital and Red Cross
Hospital, Solna, Sweden.
Adults diagnosed with
lymphedema >6months.

Inter-rater reliability:
Using ICC for physical,
psychosocial and
practical domains on the
shorter instrument were
0.88 (p<0.01), 0.87
(p<0.01), and 0.87
(p<0.01).
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including
stability over
time and
concurrent
validity.

N: 200 (100/site)
contacted, 130
participated.

Cronbach’s α:
0.88, 0.92, 0.88 –
Physical, psychosocial,
& practical domains,
respectively.

correlation with the
SF-36 for all
domains.

treatment, not
verifiable. Patients
may have improved
due to time of year or
expectations effect.
Did not assess the
sensitivity of the
LyQLI.

ULL-27 is shown to
be valid and
reliable. Scores for
physical and social
dimensions
significantly
correlated to illness
severity. Social
dimension is
sensitive to clinical
changes in
lymphedema while
physical and
psychological
dimensions do not
change in clinically
stable patients.

Measurement tool
was developed in
France for French
speaking patients
limiting
generalizability for
practitioners in other
countries.
Methodology &
results for
comparison to SF-36
are brief, limiting
ability to reproduce
methods or compare
results. Setting is
unclear. Poor quality
of research
translation from
French to English
language affecting
interpretation of
results.
The study failed to
identify limitations in
the design, such as all
clients recruited from
one cancer center.

Concurrent Validity:
Scores of the three
domains of the shortened
LyQLI with scores of the
PCS and MCS in the SF36 were all rs > 0.60.
Launois,
Megnigbeto,
Pocquet, &
Alliot
(2002), L

Administer
validity
testing as a
final step in
development
of ULL-27

Correlation
al study
AOTA
Level:
IV
Pyramid
Level: D2

ULL-27
Compared
against SF36, GSI,
ACS, GCI

Population:
Women aged > 18 yo.
(average age = 61 yo.) of
all educational levels
previously treated with
surgery, radiotherapy,
chemotherapy, or
hormone therapy.
Diagnoses:
Upper limb lymphedema
stages 1-4, 2° to BC.
47% had a history of
lymphangitis.

Internal Consistency:
Physical = 0.93
Psychological= 0.86
Social = 0.82
(Cronbach’s α)

Effect Size in patients
who improved clinically:
Physical = 0.58
Psychological= 0.62
Social= 0.38

Setting: multiple centers
N = 301

Morrow,
Lindke, &
Black
(1992), QLR

Examine
psychometric
s of the FLIC,
including

Correlation
al Study
AOTA
level: IV

FLIC

Population: Patients
being treated w/
chemotherapy.
Age: 18-76.

Construct validity:
18/22 questions had
factor loading > 0.40 on
only 1 of 5 factors. 4
questions addressing

FLIC appears to be
a valid and
internally consistent
instrument. There is
strong evidence for
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construct
validity

Pyramid
level: D2

Setting: University of
Rochester Cancer
Center.
N: 489, originally
recruited 530

Patoo,
Allahyari,
Moradi, &
Payandeh
(2015),
APJCP

Assess the
validity of the
FACT-B
when used for
Iranian
women w/
BC.

Correlation
al study
AOTA
level: IV
Pyramid
level: D2

FACT-B
(Persian
Version)
compared
against
HADS
anxiety and
depression
and the
EORTC
QLQ-C30

Population/Setting:
Women recruited from
oncology clinics and
hospitals in Iran.
Pathologic diagnosis of
cancer.
N: 300

cancer had loading >
0.40 on 2+ factors.
Criterion-related
validity: Low sideeffects and anxiety result
in higher QoL scores.
Females had higher
physical & social
functioning scores.
Internal consistency:
Cronbach’s α = 0.90
(original sample), 0.94
(validation sample)
Internal consistency:
Cronbach’s α: 0.93-0.63
for subscales, 0.92 total
scale.
Convergent validity:
All interscale
correlations p<0.01,
except SFWB and PWB
Discriminant validity:
correlation between all
Persian FACT-B
subscales and HADS
statistically significant.
Concurrent and
construct validity:
Except SFWB, all
subscales of FACT-B
significantly correlated
w/ EORTC-QLQ-C30
Fit indices showed
modest fit of the model.

construct validity,
and factors were
sensitive to
meaningful
differences. The 4
cancer related
questions should be
omitted to create a
better fit of the data
to the factor model.

The study looked
broadly at cancer,
limiting
generalizability to
lymphedema.

The Persian version
of FACT-B is
reliable and valid in
assessing HRQoL of
Iranian BC patients.

Validation of a
translated version of
FACT-B, not
original. Cultural
differences of Iranian
women, including
taboo nature of
speaking about
sexuality limits
generalizability to
USA. Study failed to
identify specific
limitations. Limited
information
regarding patient
recruitment process.
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Sprangers,
Groenvold,
Arraas,
Frnklin,
Velde,
Mulle…
Aaronson,
(1996), JCO

Develop a BC
specific QoL
questionnaire
used in
tandem w/ the
EORTC
QLQ-C30

AOTA
level:
IV
Pyramid
level:
D2

QLQ-BR23

Dutch Sample:
Participants had BC and
were receiving either
radiotherapy or
chemotherapy.
Setting: Antoni van
Leeuwenhoek Hospital,
Amsterdam
N = 170
Spanish Sample:
Participants had BC and
were receiving either
radiotherapy or
chemotherapy.
Setting: Hospital de
Navarra, Pamplona
N = 168
American Sample:
Participants had BC and
were either about to start
treatment or were in
follow up care.
Setting: M.D. Anderson
Cancer Center, Houston,
TX
N = 158

Reliability:
Cronbach’s α:
Dutch = 0.57 - 0.89
Spanish = 0.46 – 0.94
American = 0.70 – 0.91
Validity:
Spanish effect sizes:
medium (0.60-0.68)
Dutch effect sizes:
medium-large (0.43-1.1)
American sample did not
achieve statistical
significance.

Validity
demonstrated by
test’s ability to
discriminate
amongst subgroups
with different
clinical statuses and
across cultures.
Reliability lowest in
Spanish sample and
highest in American
sample.

Scores measuring
clinical state of
health were not
completely
comparable as
Spanish patient
information was
provided by
physician and Dutch
sample was
interviewer based.
Questions about
sexuality were
considered too
intrusive for some
female participants
and were
unanswered.

19

LYMPHEDEMA HRQOL ASSESSMENTS
Van de Pas,
Biemans,
Boonen,
Viehoff &
Neumann
(2015), P

Viehoff,
Genderen, &
Wittink,(200
8), L

Test the
psychometric
properties
and validate
use of a
Dutch
translation of
the
LYMQOL
Questionnaire

Validate a
version of the
ULL-27
translated to
Dutch

Correlation
al study

LYMQOL
SF-36

AOTA
Level: IV
Pyramid
level: D2

Correlation
al study
AOTA: IV
Pyramid:
D2

ULL-27
(Dutch
version)
Compared
against the
SF-36

60 patients diagnosed at
an academic institution
completed questionnaire.
Response rate was
88.2%, 70% were
women.
Mean age: 60
SD: 15.6 years
Range: 19-92. Most had
bilateral leg 2°
lymphedema. Classified
according to duration of
lymph:
0-5 yrs: 19.4%
5-10 yrs: 22.4%
10-20 yrs: 28.4%
20+ ys: 29.9%
Most patients wore
compression stockings
Population:
Women (mean age= 59)
fluent in Dutch. 94% had
axillary surgery.
Diagnosed w/ unilateral
edema of the UE
Setting:
29 lymphedema
physiotherapy specialist
practice settings
N= 84
Comparison Population:
An age-matched group
of women without
symptoms
N=61

Internal Consistency:
Cronbach’s α: 0.89
Test-retest reliability:
Excellent, w/ rho >0.8
for all domains, and
overall QoL was good,
w/ rho >0.7

The Dutch
LYMQOL is a
feasible, reliable,
and valid tool in the
assessment of
HRQoL in patients
w/ LE lymphedema.

Generalizability
limited due to nonrandomized sample
and Dutch population

No distinction
between 4 grades of
severity in Dutch
version (inconsistent
with original version
of ULL-27), similar
internal consistency
(good) to original
version, physical
domain of ULL-27
poorly correlated to
SF-36

Participant
characteristics
(amongst types of
severity) do not
match that of the
original validation
study making direct
comparison
impossible;
comparison group
consisted of
physiotherapist’s
friends and family
introducing bias

Validity:
The LYMQOL
correlated well w/ the
PCS and moderately
well with the MCS of the
SF-36

Internal consistency:
good; all > 0.70
(Cronbach’s α)
Item domain internal
consistency sufficient
except for 2 questions
(#20 & #22)
Concurrent Validity:
domains of Dutch ULL27 significantly
correlated to 5 of 8
corresponding SF-36
domains
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Weiss &
Daniel
(2015), L

Assess the
reliability and
validity of the
LLIS as a
conditionspecific
instrument
for persons
with
lymphedema.

Correlation
al cohort
study
AOTA
level: IV
Pyramid
level: D2

LLIS
Compared
to:
LYMQOL
EORTC
QLQC30
DASH
LEFS

Population/Setting:
Adult patients w/
lymphedema (except
controls which
comprised of patients at
risk for lymphedema)
recruited from
lymphedema therapy
clinics across the US.

Internal consistency:
Cronbach’s α: .841-.926
Test-retest
reliability: .97-.99
Construct validity:
r = .706-.830

The LLIS was
demonstrated to be a
valid and reliable
QoL tool for
assessing severity of
impairment among
patients w/
lymphedema.

Most participants
were white females
limiting
generalizability
across gender and
race.

Neither
questionnaire can
replace the other for
women with BC.
The modest
correlations between
the SF-36 and FLIC
suggest they
measure somewhat
different aspects of
HRQoL. The FLIC
was more sensitive
to differences in
EWB. Both FLIC
and SF-36 were able
to distinguish
deficits in physical
functioning in the
group with
lymphedema.

Clinic data
influencing HRQoL
was not collected,
limiting
generalizability. Only
compared two
instruments, limiting
convergent validity
measures. Population
limited to women w/
BC more than 3
months post-surgical
intervention.

N=102

Wilson,
Hutson, &
VanStry
(2005), PT

Assess
convergent
validity and
discriminativ
e validity of
SF 36 and
FLIC

Correlation
al study
AOTA
level: IV
Pyramid
level: D2

RAND 36Item Health
Survey
(SF-36)

Population: Women w/
BC, who received
surgical intervention >
3mo prior.
Age: 18-65yo.

FLIC
Setting: National Cancer
Institute-designated
Comprehensive Cancer
Center
N: 110 (n=32 w/ 2º
lymphedema)

Bivariate correlations:
SF-36 mental & physical
component tau-b=0.247.
SF-36 mental component
& FLIC total taub=0.490. SF-36 physical
component & FLIC total
tau-b=0.556.
Convergent/Divergent
Validity:
Comparisons of pairs of
subscales of QoL
domains showed
convergent correlations
in the physical domain
(𝑥 2 =20.48, p<0.001),
mental well-being
domain (𝑥 2 =7.68,
p<0.01), & social
functioning (𝑥 2 =4.45,
p<0.05). However,
convergence within the
general health dimension
was not significant
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(𝑥 2 =3.27, p < 0.1),
indicating these similarly
named subscales
measure different QoL
dimensions in this
sample.
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CAT Table 5: Systematic Reviews
Author(s), Year Study
Objectives

Davies, Ryans,
Levenhage, &
Perdomo (2014),
RO

Study Design/ Number of Papers
Level of
Included, Inclusion and
Evidence
Exclusion Criteria

Identify outcome Systematic
measures
Review
targeting QoL
and function
AOTA Level: I
specific to UE
secondary
Pyramid Level:
lymphedema,
D1
review
psychometrics,
and make clinical
recommendations

Papers Included: 42

Outcome
Measures

FACT-B +4,
DASH, ULL-27,
Lymph-ICF,
Inclusion Criteria:
UE secondary lymphedema, LYMQOL
female, adult, breast
neoplasm,
Exclusion Criteria: primary
lymphedema, LE, venous,
male gender, lack of
psychometric properties

Summary of Results

Limitations

FACT-B+4
Limited to UE assessments
Highly recommended due to and BCRL, Recommendations
test-retest reliability, overall based on Breast Cancer EDGE
internal consistency;
Task Force ratings and
unknown clinical utility
definitions for clinical utility
DASH
could contain bias.
Highly recommended for
test-retest reliability, internal
consistency, validity, and
sensitivity to change
(MCID=10.2); good clinical
utility
ULL-27
Unable to recommend at this
time
Lymph-ICF
Unable to recommend at this
time (no sensitivity reported,
lack of clinical use in U.S.)
LYMQOL
Unable to recommend at this
time (in development phase)
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Oliveira, Costa,
Gafundes, &
Cabral (2015),
QLR

Identify BC
specific
questionnaires
that have been
cross-culturally
adapted and
critically
analyzed for
quality of
translation,
adaptation, and
evaluation of
measurement
properties

Pusic, Cemal,
Identify studies
Albornoz, Cano, describing
Sulimanoff,
HRQOL
Hernandez,
outcomes in
Massey, Cordeiro,BCRL patients,
Morrow, &
assess quality of
Mehrara
studies, & assess
(2013), JCS
PRO instruments

Systematic
Review

Papers Included:
24
Inclusion Criteria:
AOTA level: I Studies from any year or
language assessing BCPyramid level: specific QoL questionnaires
D1
translated into a language
besides source language.
Studies exclusive to women
with BC.

EORTC QLQBR23
FACT-B
FACT-B+4
IBCSG
LSQ-32
QLICP-BR

Systematic
Review

4 generic
HRQOLs, 9
oncologyspecific, 2
BCRL-specific

39 studies; inclusions:
BCRL, described HRQOL
outcomes among BCRL,
AOTA Level 1 English only, formally
developed, valid PROs.
Pyramid level Exclusion: No conference
abstracts, no BC in men
D1

Shortcomings in global BC Studies evaluated by one set
QoL instruments. Over half of guidelines. Cross-cultural
of articles had no
validation and measurement
information for translation properties of a QoL
and cross-cultural
questionnaire are complex and
adaptation. EORTC QLQ- subject to misinterpretation.
BR23 in Spanish and Korean
highest level of translation
and cultural adaptation.
Internal consistency doubtful
in 15 articles. Construct
validity adequate in 3 studies
(FACT-B, EORTC, & QLQBR23). 4 of 8 articles
positively reported
reliability.
ULL-27 recommended b/c of BCRL only, English only,
strong psychometric
women only. No nonproperties, generic PRO
validated, modified
should be used alongside
standardized instrument.
condition-specific PRO
The article did not contain list
of databases used for
identifying articles.
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Treanor &
Review studies
Donnelly (2015), investigating the
validity,
QLR
reliability, and
sensitivity of the
SF-36 and its
derivatives
among BC
survivors.

Systematic
Review

Papers included: 7

PubMed, MEDLINE,
AOTA level: I EMBASE, CINAHL,
PsycINFO and the Social
Pyramid level: Sciences Citation Index
D1
search engines were used
with keyword search terms.
Reference lists of retrieved
articles were reviewed for
relevant contributing
articles.
Inclusion criteria:
Articles including survivors
of BC; using SF measures to
assess psychometrics of
other measures, peer-review
articles
Exclusion Criteria:
No exclusions were made
due to the small number of
papers identified

SF-36
partial SF-36
SF-12
FACT-B
FACT-G

Articles which scored ‘poor’
on one item on the COSMIN
SF-36 and SF-12 subscales checklist may have received
ranged from acceptable to an overall ‘poor’ rating.
good across different
Inclusion of additional studies
language and ethnic groups. which did not primarily assess
psychometric properties of SF
Concurrent validity:
may be questionable. Many
Good inter-correlation
psychometric properties of the
between Dutch SF-36 and SF-36 were not assessed in the
lymphedema-specific
breast cancer population.
measures (ULL27 and
Lymp-ICF), but less strong
correlation with physical
subscales. SF-36
discriminated between BC
survivors w/ and w/o
lymphedema on physical
subscales.
Internal Consistency:

Conclusions: SF measures
were found to have good
psychometric properties and
would provide a useful aide
for health care providers to
assess health-related
outcomes of breast cancer
survivors in their care.
Further research needed to
identify psychometric
performance of SF-36 on
cancer-related effects.
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Summary of Study Designs of Articles Selected for the CAT Table
Pyramid Side

Study Design/Methodology of Selected Articles

Experimental

___Meta-Analyses of Experimental Trials
___Individual Randomized Controlled Trials
___Controlled Clinical Trials
___Single Subject Studies

Outcome

___Meta-Analyses of Related Outcome Studies
___Individual Quasi-Experimental Studies
___Case-Control Studies
___One Group Pre-Post Studies

Qualitative

___Meta-Syntheses of Related Qualitative Studies
___Small Group Qualitative Studies
___brief vs prolonged engagement with participants
___triangulation of data (multiple sources)
___interpretation (peer & member-checking)
___a posteriori (exploratory) vs apriori (confirmatory)
interpretive scheme
___Qualitative Study on a Single Person

Descriptive

_4_Systematic Reviews of Related Descriptive
Studies
15_Association, Correlational Studies
___Multiple Case Studies (Series), Normative Studies
___Individual Case Studies

Comments:
The majority of studies were correlational studies evaluating psychometric
properties. Four studies were literature or systematic reviews comparing
psychometrics across assessments.
AOTA Levels
I- 4
IIIIIIV- 15
V-

Abbreviation

Full Phrase

1°

Primary

2°

Secondary

ACS

Patient's arm comfort scale

ALMANAC

Axillary lymphatic mapping against nodal axillary clearance

BC

Breast cancer

BCRL

Breast cancer related lymphedema

Number of
Articles
Selected

19

TOTAL =19
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COSMIN

Consensus-based Standards for the Selection of Health Measurement Instruments

DASH

Disability of Arm, Shoulder, and Hand

EDGE

Evaluation database to guide effectiveness

EMR

Electronic medical record

EORTC QCQBR23

European Organization for Research and Treatment of Cancer-specific quality of life
questionnaire- breast cancer 23

EORTC QCQ-C30

European Organization for Research and Treatment of Cancer-specific quality of life
questionnaire-cancer 30

EWB

Emotional well-being

FACT-B, FACTB+4

The Functional Assessment of Cancer Therapy - Breast

FACT-G

Functional Assessment of Cancer Treatment - General

FLIC

Functional Living Index-Cancer

FWB

Functional well-being

GCI

Global clinical impression

GSI

Global symptom index

HADS

Hospital Anxiety and Depression Scale

HOS

Health outcome survey

HRQoL

Health-related quality of life

IBCSG

International Breast Cancer Study Group

ICC

Intra-class correlation

LE

Lower extremity

LEFS

Lower extremity functional scale

LLIS

Lymphedema Life Impact Scale

LSQ-32

Life Satisfaction Questionnaire – 32

Lymph-ICF

Lymphoedema Functioning, Disability, and Health Questionnaire

Lymph-ICF-LL

Lymphoedema Functioning, Disability, and Health Questionnaire for Lower Limb
Lymphedema

LYMQOL

Lymphedema Quality of Life Measure for Limb

LyQLI

Lymphedema Quality of Life Inventory
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MCID

Minimal clinically important difference

MCS

Mental component summary measure

NHP

Nottingham Health Profile

PCS

Physical component summary measure

PSR

Performance status rating

PRO

Patient reported outcomes

PWB

Physical well-being

QLICP-BR

Quality of Life Instrument for Cancer Patients-breast cancer

QoL

Quality of life

SD

Standard deviation

SEM

standard error of measure

SF

Short Form

SF-12

Short Form-12

SF-36

Short Form-36

SFWB

Social and family well-being

SLQOLI

Swedish Lymphedema Quality of Life Inventory

TOI-PFB

Trial Outcome Index – Physical/Functional/Breast

UE

Upper extremity

UK

United Kingdom

ULL-27

Upper limb lymphedema measure

w/

With

w/o

Without

yo

years-old

Summary of Key Findings:
Summary of Experimental Studies
N/A
Summary of Outcome Studies
N/A

27

LYMPHEDEMA HRQOL ASSESSMENTS
Summary of Qualitative Studies
N/A
Summary of Descriptive Studies
The DASH questionnaire consists of 30 items that evaluate symptoms and functional tasks associated with
limitations in the arm, shoulder, and hand. It demonstrated strong reliability, validity, and sensitivity to change
in women with BC. The tool has been widely used in BC research and clinics on patients with and without
lymphedema since its inception in the mid-1990s (Coster, Poole, & Fallowfield, 2001; Davies et al., 2015).
The Functional Living Index-Cancer (FLIC) is a broad-based assessment tool developed in the early 1990s to
measure HRQoL for patients with cancer. The physical function domain of the assessment discriminates
patients diagnosed with lymphedema. The instrument is more sensitive to emotional well-being than the SF36 (Morrow, Lindke & Blacke, 1992; Wilson, Hutson & VanStry, 2005).
The FACT-B+4 consists of 36 items with four questions addressing swelling and tenderness in the arm. It was
developed to supplement the FACT-B, the original multi-dimensional breast cancer QoL tool. It has been
tested on women with lymphedema secondary to BC. This tool has strong reliability, internal consistency, and
sensitivity to change over time with women with BC (Brady et al., 1997; Coster, Poole, & Fallowfield, 2001;
Davies et al., 2015).
The LLIS is a new lymphedema-specific assessment tool designed for use in the U.S. for calculating G-codes.
The LLIS was compared to the LYMQOL, EORTC QLQ30, DASH, and LEFS and demonstrated good
validity and reliability for assessing lymphedema severity among adult patients (Weiss & Daniel, 2015). The
LLIS correlated more strongly with the LYMQOL than the others, except for the functional domain of the
DASH. A limitation was a sample comprised largely of white females (Weiss & Daniel, 2015).
The LyQLI is a new lymphedema-specific Swedish assessment tool adapted from the SLQOLI as of 2015. It
was compared to the SF-36 and shown to have good reliability and validity. Results indicate that the
assessment tool holds promise. Sensitivity not tested (Klernas, Horstmann, & Kristjansson, 2015).
The Lymph-ICF was created in 2011 for patients with upper limb lymphedema (Devoogdt et al., 2011). Initial
psychometric testing revealed strong test-retest reliability, internal consistency, content validity, and construct
validity when compared against the SF-36 (Davies et al., 2015; Devoogdt et al., 2011). Women and Dutch
populations were predominantly studied when establishing psychometric properties of this measurement
device. There is no evidence of clinical use in the U.S. (Davies, 2015).
The Lymph-ICF-LL was created in 2014 for patients with lower limb lymphedema (Devoogdt et al., 2014).
Initial psychometric testing demonstrated that it was a reliable and valid measure, but similar to the LymphICF, this instrument has only been tested on Dutch populations with lymphedema secondary to axillary
dissection (Devoogdt et al., 2014).
The ULL-27 was developed in France in 2002 for measurement of upper limb lymphedema. It tests physical,
social, and psychological domains. Initial testing of the psychometrics report that the test is reliable,
consistent, and responsive to change (Launois et al., 2002). This measurement tool has been translated into
English and Dutch, but only the Dutch version has undergone psychometric testing after adaptation and
translation (Davies et al., 2015). The Dutch version translation demonstrated internal consistency on all items
with exception of two questions which are addressed by Viehoff, Van Genderen, and Wittink (2008). The
physical domain of this version poorly correlated to the SF-36 (Viehoff et al., 2008).
The LYMQOL’s psychometrics were listed by a secondary study, but the primary study was not obtained
through available resources. However, a Dutch version that tested psychometric properties demonstrated good
validity and reliability for assessing HRQoL in patients with lower limb lymphedema (Van de Pas, Biemans,
Boonen, Viehoff, & Newmann, 2015). The LYMQOL was developed with a structure similar to EORTC
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QLQ-C30. Results state assessment is a validated QoL for use with persons with lymphoedema, and
systematic review cites similar findings (Davies, Ryans, Levenhagan, & Perdomo, 2014).
The EORTC developed the QLQ-C30 and the QLQ-BR23 to measure quality of life among patients with BC. The
test has been translated to various languages and in one study demonstrated good reliability, clinical, and crosscultural validity for the Dutch, Spanish, and American versions (Sprangers et al., 1996).
Implications for Consumers:
While secondary lymphedema is often associated with patients undergoing cancer treatment, it is also
experienced as a result of trauma or parasitic infection or where there is damage to the lymphatic
system (Morgan, Franks, & Moffatt, 2005). Swelling, skin changes, fibrosis, sensory impairments, pain,
discomfort, heaviness in the affected limb, and secondary infections are common symptoms associated with
lymphedema (Morgan et al., 2005). Understanding the HRQoL for patients with lymphedema is consistent
with client-centered treatment. Since improvement of HRQoL is the primary aim of lymphedema treatment, it
is imperative that valid and reliable measures are used to best capture this condition-specific experience. This
critical appraisal demonstrates that outcome measurements for lymphedema treatment are varied in their
approach (generic versus condition-specific) and include different areas of HRQoL. Consumers should take
note of the types of outcome measures used by lymphedema therapists during treatment and evaluate the
accuracy of results against subjective experience. If a patient with lymphedema feels that outcomes are not
consistent with instrument results, or that a selected measure is not appropriate for his or her case, this
critically-appraised topic can serve as a resource for advocacy. A patient with lymphedema should advocate
for the most valid and reliable measurement of outcomes for purposes of adjusting treatment for optimal
gains.
Implications for Practitioners:
This critically appraised topic is especially important to occupational therapists specializing in lymphedema.
The 2013 mandate by Medicare to report G-codes, a functional status for patients across points of treatment,
highlights a trend towards defining successful treatment as it relates to function (Doucet, 2014). This focus
on functional activities has been a tenet of occupational therapy since its inception. Doucet (2014) describes
this as a “critical” time for occupational therapists to assert the unique scope and domain of function in their
practice. In order to capitalize on this opportunity, the use of valid and reliable measures to document
function is essential. Psychometrically-sound measurement instruments arm practitioners with objective data
to quantify the effectiveness of interventions on everyday functioning. This information works to
demonstrate the effects of treatment to third-party payers for purposes of reimbursement.
Practitioners specializing in lymphedema therapy define function as it relates to HRQoL. Hence, it is
fundamental for this sub-field of occupational therapy to incorporate outcome measures that reliably and
accurately target condition-specific HRQoL. Since research on condition- specific measurements is still in its
infancy, practitioners should evaluate the characteristics of each device against a client's specific
presentation (i.e., comorbidities, upper limb versus lower limb, etc.) to select the most appropriate
measurement tool. Practitioners working with female patients experiencing lymphedema in the upper limb
secondary to BC will have a stronger body of evidence-based outcome measures to select from (FACT-B+4,
EORTC QLQ-BR23) (Coster et al., 2001; Oliveira et al., 2015; Patoo, et al., 2015).
Practitioners should stay abreast of research developments surrounding this topic since the recent influx of
promising lymphedema-specific measurements and cultural adaptations for these measures indicate that
further psychometric testing is underway (Devoogdt et al., 2014; Launois et al., 2002; Oliveira et al., 2015;
Viehoff et al., 2008).
Program development that establishes protocols for selecting outcome measurements used during evaluation
and assessment would be appropriate based on this critically-appraised topic. In conclusion, this criticallyappraised topic supports the use of the DASH for patients with lymphedema when lymphedema is secondary
to breast cancer. For patients with lymphedema not secondary to BC, this critically-appraised topic
recommends adoption of the LLIS. Future program development is recommended to outline decision-making
protocols for outcome measures that are awaiting further psychometric testing (Lymph-ICF, Lymph-ICF-LL,
LyQLI, & ULL-27). Development of these protocols will allow all lymphedema patients within a setting to
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be assessed with reliable and valid measures in a consistent manner. In addition, implementing these
assessments in a systematic way will provide cohesion across therapists and settings and communicate
intervention outcomes with a variety of disciplines along the continuum of care.
Implications for Researchers:
This critically-appraised topic has multiple implications for researchers. Due to the limited amount and types
of research surrounding each lymphedema-specific measure, further research is needed to evaluate the
psychometric properties of the LLIS, Lymph-ICF, Lymph-ICF-LL, LYMQOL, and ULL-27. Furthermore,
there is a need for studies addressing the cultural adaptation and translation for these types of measures
(Oliveira et al., 2015). Overall, it appears that generic measurements such as the SF-36 and DASH are reliable
and valid for assessing HRQoL, and are often used as a comparison against newer measurement tools (Davies
et al., 2015; Devoogdt et al., 2014; Launois et al., 2002; Viehoff et al., 2008, etc.). Through the use of wellstudied generic tools, researchers should investigate the aforementioned lymphedema-specific measurements
and encourage further development for distinct characteristics of HRQoL in patients with lymphedema. This
will provide practitioners with measures that objectively demonstrate the effects of intervention as related to
function during a time of utmost importance (Doucet, 2014).
Bottom Line for Occupational Therapy Practice/ Recommendations for Better Practice:
Occupational therapists specializing in lymphedema can apply information from this critically-appraised
topic to better inform decisions when selecting outcome measures on a patient’s HRQoL. Lymphedemaspecific measurement devices are ideal for most accurately quantifying results of therapy (Launois et al.,
2002), but many are still awaiting adequate psychometric backing for full implementation at this time. The
DASH, a generic HRQoL measure that is widely used in practice, has demonstrated excellent reliability and
validity on women with lymphedema secondary to BC (Davies et al., 2015). This critically-appraised topic
implies that better practice in lymphedema therapy can be obtained by implementing this generic HRQoL for
use with patients with BC. For patients who do not have lymphedema secondary to BC, it is recommended to
use a lymphedema specific HRQoL measure to obtain a more specific and personalized picture of the impact
that lymphedema has on the patient. Thus, for these purposes, the research indicates that the LLIS is
currently the best route, excluding use with patients with BC for which the DASH would be a better
assessment tool. These conclusions were reached after reviewing psychometric properties, ease of clinical
use, and generalizability to populations in the U.S. With further testing in the U.S., the FACT B +4 could be
a viable option for patients experiencing lymphedema secondary to BC. Further details on the data used to
reach these recommendations are presented in Table 1.
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Involvement Plan
In 2013, Medicare mandated that therapists report G-codes, a functional status code for patients across
points of treatment. Our review, which revolved around evaluating psychometrically-sound measurement
instruments used by lymphedema specialists to measure HRQoL, led to the recommendation of two assessments: the
DASH and the LLIS. In deciding upon the best route to translate knowledge gained from our research, we met with
Heidi Shaffer, our collaborating clinician for this project. The process for our involvement plan has been outlined in
Table 2. We began our dialogue with Heidi around the fact that the Gig Harbor Lymphedema MultiCare clinic
already purchased the LLIS, a lymphedema-specific measurement tool. In highlighting this fact to Heidi, we learned
of current obstacles to full implementation of this assessment.
As Heidi explained, the LLIS G-code calculator was not embedded into Epic®, the EMR system used by
MultiCare, making the assessment difficult to utilize. Currently, some therapists substitute this standardized
assessment with their clinical reasoning and a G-code calculator independently created by MultiCare for reporting
G-codes. Heidi indicated that the LLIS had been requested to be inputted into the computer system, but the request
had not yet been implemented. Hence, even though the LLIS has its own G-code calculator, it was not readily
available for all clinicians to use due to the fact that their computer system had not been updated. At this point in our
conversation, Heidi pointed out that Sherri Olsen, Director of Physical Medicine and Rehabilitation, would be the
appropriate person to talk to about our knowledge translation process to implement our recommendations. Related
tasks and products for this meeting are detailed in Table 2, Items 1-2.
The other assessment recommended by our research was the DASH, a generic upper extremity HRQol tool
which does not come with its own G-code calculator. Heidi was excited about the idea of creating a G-code
calculator for this assessment in order to promote its efficiency, but reiterated that we should meet with Sherri as a
first step. Hence, we learned that we had an opportunity to introduce our knowledge translation plan to a person who
could potentially facilitate a largescale change, but that a barrier existed in the process of embedding code into the
Epic® computer system. This added a new dynamic to our knowledge translation process as we considered how to
best present our research to Sherri to effect change, and how we might be involved with this third party of computer
technicians.
Next, Heidi suggested we provide an in-service presentation and printed materials to MultiCare
lymphedema therapists to describe administration of the DASH and the LLIS. She thought that outlining the pros
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and cons for each assessment in addition to providing a pamphlet that therapists could quickly refer to would be
helpful. These next task steps and products are elaborated upon in Table 2, Item 3.
Finally, we discussed the possibility of presenting our findings at an AOTA conference. To this end, Heidi
recommended we also look into submitting our research to the National Lymphedema Network Conference
scheduled for 2018. This last step is outlined in Table 2, Item 4.
As evident from our conversation with Heidi, there are contextual factors to our knowledge translation
process that we had not previously accounted for. As clinical use of an assessment is largely dependent on its
usability within an electronic documentation system, there are cultural, technical, and administrative factors not only
within the MultiCare organization itself, but also within the Epic® organization to consider. We felt that if we were
able to effect change on an organizational level by integrating the LLIS and DASH assessments into the
documentation system, there would remain individual factors to analyze. Current practice of applying clinical
reasoning to produce HRQoL descriptions and corresponding G-codes implies that an internal process exists that
may be difficult to change. Thus, our knowledge translation may have been affected by the long held practices of the
lymphedema therapists themselves, which is consistent with the ARC model for knowledge translation (as cited in
Palinkas & Soydan 2012).
While these contextual factors presented possible barriers, they also provided valuable information to
inform our strategy and planning process. Upon meeting with Sherri, we had planned to inquire as to how we could
best aid in pushing Epic® to embed the two assessments and their corresponding G-code calculators into the
computer system. During our in-service presentation and through distribution of printed materials, we demonstrated
that adoption of the DASH and LLIS supports evidence-based practice and, each with its own G-code calculator,
will aid in the efficiency of the practicing clinicians. If we pursue an application to the National Lymphedema
Network conference and AOTA conference, we hope to further impart this knowledge translation to a wider
audience. In terms of evaluating the outcomes of these various activities, we followed up with a satisfaction survey
at the end of our in-service presentation.

Knowledge Translation Activities and Products
The main goal of our knowledge translation process was to come ‘full circle’ by applying our evidencebased recommendations to G-codes for Medicare reporting, as this was a piece of the original research question
from our collaborating clinician. Calculating accurate G-codes rests on the use of psychometrically sound
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assessments, thus we felt G-codes would also be a logical avenue to bring about evidence-based change for the
MultiCare lymphedema therapists. After meeting with Heidi on February 13, 2017 we learned that neither the LLIS
nor the DASH were features of Epic®, the electronic medical records system used by MultiCare lymphedema
therapists. To increase the ease in utilizing our recommended standardized assessments, we established a second
goal for our knowledge translation process: to make these two assessments readily available within the Epic®
system. After hearing about this proposal, Heidi recommended we meet with Sherri Olsen to discuss the process to
bring about this change.
The first stage of our knowledge translation process aimed to create a G-code calculator for the two
recommended assessments used to measure HRQoL for patients with lymphedema: the LLIS and the DASH. We
learned that the LLIS has a G-code calculator embedded within its e-format, but clinicians at MultiCare did not have
a readily available G-code calculator for the DASH. Upon researching G-code calculations, we quickly learned that
G-code modifier “cheat sheets” had already been created for a variety of assessments. As the DASH produces a
score on a 100 point scale and modifiers are coded in units of 10 from 1 to 100, converting DASH assessment scores
to a G-code modifier score was more of a seamless process than we anticipated. We verified our findings,
reproduced the calculations, and distributed small laminated copies of the DASH ‘cheat sheets’ for clinicians during
our in-service presentation. This was the first product of our knowledge translation process.
During an in-service presentation held at Tacoma General Hospital, we spent about 30 minutes with eight
practitioners highlighting our research and the take-aways from our findings. We prepared a PowerPoint
presentation to aid us in explaining our research process, findings, and implications, but experienced technical
difficulties in showing this during our presentation. As a result, we forwarded a copy of the PowerPoint presentation
to Heidi and Sherri following the in-service. While conversing with the lymphedema therapists, we learned that
standardized assessments are typically administered to patients on a laminated copy followed by the therapists’ entry
of the scores into Epic®. We also learned that therapists often use the Quick DASH in lieu of the DASH, an
assessment our research review did not cover. While these two unexpected hurdles arose during our in-service
presentation, the therapists seemed very interested in the table we had created and very receptive to the information
provided regarding the recommended assessments. A satisfaction survey was used to gauge the delivery and utility
of the information presented. This in-service presentation, accompanying PowerPoint, and satisfaction survey served
as the second piece of our knowledge translation process.
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The final stage of knowledge translation for this research revolved around an hour long meeting with Sherri
at the University of Puget Sound campus on April 14, 2017 with George Tomlin, our facilitating faculty member.
We found this meeting to be integral for obtaining insight into the realities for practicing lymphedema therapists.
Sherri described that a common barrier to accessing lymphedema therapy services often lies in the referral process
from oncologists. She explained that doctors are often concerned about the load of appointments that their patients
must attend and often do not always understand the role of occupational and physical therapy in addressing
lymphedema at the critical juncture early on in their diagnosis. Often, she explained, patients do not experience
lymphedema until weeks or even months after seeing their doctor, and thus lymphedema therapy does not become
an immediate issue for them to address. Sherri explained her involvement in current research regarding “prehab” for
lymphedema treatment, and the desire to provide hard evidence showing the benefits of therapy early on to doctors.
She explained that our research concerning HRQoL for patients with lymphedema has aided her in the early process
of her research to identify a HRQoL measure for use in her study. While this confirmed the utility in our research
implications for other researchers, this meeting also revealed an unexpected difficulty to our knowledge translation
process as related to the bigger picture that practitioners work in: if clients are not receiving therapy services until a
more chronic stage in the course of their lymphedema, then an HRQoL is less likely to demonstrate changes in
function along the course of therapy in the way that it likely would if patients were referred earlier in the course of
lymphedema management. Overall, this could potentially lead to a smaller change in function as illustrated by Gcode reporting when, in actuality, the lack of change is a result of the late referral to therapy. This meeting brought a
new perspective to how our research, a piece of the puzzle that is the world of lymphedema therapy, exists in
relation to larger systemic forces at play.
In addition to this insight, meeting with Sherri allowed us to follow up on our final goal of knowledge
translation: to facilitate making the DASH and LLIS readily available within the Epic® system. Sherri suggested we
craft an email with detailed instructions that she could forward to the infomatic specialists at Epic®. This email
became the final step in our knowledge translation process. A remaining unforeseen difficulty in this process lies in
not knowing if the Epic® computer programmers were successful in implementing our directions and if they were,
how therapists understood or were informed about this new feature incorporated into Epic®. We also had not
anticipated the amount of time and effort involved in preparing an email with explicit, detailed information to
program the assessments into Epic®, and imparting a change to the way standardized assessments are administered
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by lymphedema therapists. Effective knowledge translation requires not only communication amongst multiple
parties for coordination purposes, but also education on processes (e.g. scoring the DASH, psychometric properties
of each assessment, etc.) to ensure fidelity.
Additional pieces of our knowledge translation include submitting our findings to the 2018 AOTA
conference next year, which we intend to complete in May when the AOTA submission guidelines become
available. We located information about to the National Lymphedema Network. However, we were unable to locate
specific information regarding submission of research.
Knowledge Translations Outcomes
At the end of our in-service presentation to the lymphedema therapists at MultiCare, we handed out a
satisfaction survey to gauge the delivery and utility of the information presented on our research findings. The
survey also provided the therapists on opportunity to reflect on their current practices and any barriers they may face
in implementing our findings. In addition, we crafted an email with detailed instructions addressed to Sherri that she
could forward onto the informatics specialists at Epic® that would allow the LLIS and the DASH along with their
G-code calculators to be embedded into the computer system for ease of use. We plan to monitor the outcomes of
this last piece of knowledge translation by remaining in contact with Sherri and Heidi via email in regards to
progress of embedding these assessments into Epic®.
Knowledge Translation Effectiveness
The purpose of our knowledge translation process was twofold: to inform clinicians of current evidence on
lymphedema HRQoL assessments and to motivate change within the MultiCare organization towards using
recommended assessments. An in-service presentation was the primary vehicle to enact both of these goals. For the
second phase of our process, we used an active strategy of writing directions to be e-mailed to informatics specialists
at Epic®. This was intended to promote change in current practices. Since this latter stage is still underway, we have
not yet been able to evaluate the effectiveness of this change. In order to measure the effectiveness the first phase of
the knowledge translation process, a satisfaction survey was implemented, the results of which informed our
conclusions. .
The satisfaction survey was created for our in-service presentation to the MultiCare lymphedema specialists
and was completed by six of the seven therapists who attended the presentation (one attended via conference call).
The survey consisted of five quantitative statements using a Likert scale ranging from strongly agree to strongly
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disagree and three qualitative questions. All of the respondents rated four of the five statements as strongly agree or
agree. These statements included: (1) The information presented today was helpful for my clinical practice, (2) I
understand the different situations for which the DASH and the LLIS are recommended, (4) I feel more informed
about current research around lymphedema HRQoL assessments after this in-service, (5) The research process,
results, and conclusions were clearly and professionally presented. The last three qualitative questions asked
included: (6) Was there any information that was not covered for which you would have liked to know more about?
(7) What barriers do you anticipate in implementing use of the LLIS or DASH? (8) Do you have any additional
questions, comments, concerns, or suggestions related to this research? The results of this satisfaction survey
provided a means for measuring the first phase of our knowledge translation process.
We were successful in some of our knowledge translation tasks and only partially effective in others. We
met the objective of educating clinicians on psychometric data for HRQoL assessments. This was measured by items
(2), (4), and (6) of the satisfaction survey which targeted the degree to which clinicians felt informed after the inservice presentation. All six respondents noted “agree” on (4) and (6) indicating that they felt more informed after
participating in our in-service presentation. Item (6) was left blank on all surveys, signaling that clinicians did not
feel there were gaps in the topics covered. Based on these results, we can conclude that we adequately informed
clinicians and that data regarding psychometric standing of lymphedema HRQoL assessments was sufficiently
translated.
The objective to motivate change within the MultiCare clinic was carried out through our in-service
presentation, creation and delivery of G-code modifier “cheat sheets,” and by taking steps toward incorporating the
recommended assessments into Epic®. The following items of the survey targeted this domain: (3) I plan to use the
DASH with the G-code modifier card in clinical practice and item (7) What barriers do you anticipate in
implementing use of the LLIS or DASH? Item (3) received one response of “strongly agree,” one response of
“agree,” three “neutral,” and one response of “disagree.” Barriers listed in item (7) were “facial edema patients,”
“time concerns,” “duration of session,” and “don’t use LLIS.” As the majority of clinicians felt neutral or disagreed
with the statement regarding their intent to use the DASH and G-code modifier card, we concluded that most
clinicians did not find the G-code modifier card useful and that they were unlikely to begin using the DASH if they
were not already. Barriers listed surrounding the element of time in a therapy session and the types of diagnoses that
the DASH and LLIS do not address further implied that our in-service presentation had not effectively considered
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these important factors when making recommendations. The issue of time efficiency arose during a question and
answer period during the in-service when a clinician inquired about research on the Quick DASH; an assessment we
had not encountered in our search. Based on this feedback, we have concluded that we have not yet met our second
objective in our knowledge translation for motivating change within MultiCare.
The goal to ignite change was elaborated on by composing an email to Epic® programmers about
embedding a feature for scoring and calculating G-codes for the DASH and LLIS in the Epic® system. As this email
has only recently been submitted, we plan to measure our effectiveness through follow up correspondence with
Sherri. Specifically, we plan to inquire about a response from programmers, if clinicians are administering HRQoL
assessments as recommended, and how clinicians will be informed of the new features in Epic®. These final stages
will allow us to evaluate our impact on motivating an adoption of the DASH and LLIS at the MultiCare clinic.
It has been reported that there is often a gap lasting up to 20 years between establishing evidence and
implementing or translating this knowledge into practice (as cited in Palinkas & Soydan, 2012). In order to address
this issue and widen the audience to whom our research is intended, a final element of our process has been to
submit our findings to AOTA for a poster presentation at their 2018 conference. For this step, we have drafted a
submission proposal for our research. We plan to submit this around the time that the application period opens
beginning May 1. Measuring effectiveness of this process will obviously take place at a future date and will likely
involve a satisfaction or impact survey at the conference should the proposal be accepted. This final step will
attempt to correct the issues we found to be ineffective during our in-service at MultiCare and will serve as an
attempt to translate our knowledge on a larger scale.
Evaluation of Overall Process of Project
The process of this critically appraised topic has been instrumental in building a sense of identity as
occupational therapists. As the project occurred in tandem with our learning about occupational therapy via
participation in an entry level master’s degree program, this research project has provided a framework of the
process involved to be an evidence-based practitioner. As we arrive towards the end of this journey, we are able to
better reflect on this process.
We began with a research question that sought to understand the utility of G-codes in a lymphedema setting
and were quickly discouraged by the initial search result of one article in the databases that used the words “Gcodes” in a way that was relevant to occupational therapy. Upon meeting with our project chair who was an expert
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on the content related to this topic, we were able to expand the way we conceptualized G-codes by focusing on the
elements of function that G-codes were targeting. The guidance we received from our project chair during this phase
led us to a new search strategy that operationalized G-codes via HRQoL assessments used in lymphedema therapy.
This step enabled us to “cast a wider net” within our search strategy that was appropriate for critical analysis and
tied back to our collaborating clinician’s initial question. In practice, this stage may represent an identification of a
problem or need for further understanding around practice trends.
After identifying the most appropriate HRQoL assessments to include in our research, we dissected them
for their reports of psychometric data to include in a CAT table format. This stage required us to consider and
analyze the research practices involved in each study for a succinct report and overall evaluation. While it felt
tedious and required meticulous attention to each article, the skills used during this phase will be required to
independently access information as practitioners. This stage also required us to continually evaluate the relevance
of articles in relation to our search criteria.
The final stage in this research project surrounding knowledge translation has allowed us to stand back and
understand how our findings fit into the bigger, ‘real world’ picture of lymphedema therapy. Meeting with a team of
lymphedema practitioners during our in-service presentation and then following up individually with Sherri Olsen
has led us to understand emerging areas for research, barriers to implementing evidence-based practice, and how
systemic factors such as the referral process to lymphedema therapy work to affect G-code scores. This stage was a
valuable first experiment in learning how to bring research most efficiently into a practice setting. We learned that
delivery needs to be engaging, motivating, and coordinated by thoughtful and efficient communication with multiple
parties.
In all, this project has been an important element in our growth as it has armed us with the tools required
and the firsthand knowledge needed to be evidence-based practitioners. While much of learning within an academic
program revolves around individual enrichment and scholastic endeavor, this project allowed us to contribute to the
field of occupational therapy as a whole as well as providing valuable education and artifacts to local communitybased practitioners within a particular hospital organization. We hope to continue to give back to our profession and
its stakeholders in similar ways throughout our career in the years to come.
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Recommendations for Future
As noted previously in our recommendation for researchers, several lymphedema-specific assessments
(Lymph-ICF, Lymph-ICF-LL, LYMQOL, & ULL-27) are still awaiting adequate psychometric backing for full
implementation in the U.S. population at this time. It would be prudent to revisit the original research question in
four to five years’ time to determine whether there are changes to our current findings.
During our meeting with Sherri, future research needs were discussed including the possibility of
identifying HRQoL assessments for patients with specific diagnoses like cancer. Applying the same research
methodology and analysis used for this project could be applied to identify HRQoL assessments within a particular
diagnostic population. Sherri noted that this information would be helpful evidence to justify use of specific HRQoL
assessments. Furthermore, this could be instrumental in obtaining reliable outcome data for intervention research
being conducted by MultiCare in collaboration with Seattle Cancer Care Alliance.
The research Sherri is currently pursuing addresses the efficacy of prehab, proactive habilitation prior to
radiation and chemotherapy treatments, for patients undergoing cancer treatment. Within this discussion, it was also
noted that additional research could be conducted regarding the benefits of prehab services for a variety of
diagnostic populations. This research would be best completed through a systematic review of the literature looking
at the potential outcomes resulting from this intervention, potentially including reduced hospitalization and
insurance costs, increased patient satisfaction, and improved HRQoL.
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treated for breast cancer: The RAND 36-item Health Survey and the Functional Living Index- Cancer.
Physical Therapy, 85, 851-859.
“*” before a reference indicates one that appears in the CAT table itself.
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Appendix A
Breast Cancer EDGE Task Force Rating Scale
(Adapted from StrokEDGE form)
Modification of Recommendation Scoring to be used with EDGE form submissions:

4 = highly recommended; the outcome has good psychometric properties and good clinical utility; the measure has
been used in research on individuals with or post breast cancer.
3 = recommended; the outcome measure has good psychometric properties and good clinical utility; no published
evidence that the measure has been applied to research on individuals with or post breast cancer.
2A = unable to recommend at this time; there is insufficient information to support a recommendation of this
outcome measure; the measure has been used in research on individuals with or post breast cancer.
2B= unable to recommend at this time; there is insufficient information to support a recommendation of this outcome
measure; no published evidence that the measure has been applied to research on individuals with or post breast
cancer.
1 = not recommended; the outcome measure has poor psychometric properties and/or poor clinical utility.
Note: Reprinted from Davies, C., Ryans, K., Levenhagen, K., & Perdomo, M. (2014). Breast cancer EDGE task
force outcomes: Quality of life and functional outcome measures for secondary lymphedema in breast cancer
survivors. Rehabilitation Oncology, 32, 7-12.
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Appendix B
Access to Recommended Assessments
Website to request access to the LLIS and G-code calculator:


http://klosetraining.com/llis-and-g-code-calculator/

Website to download the DASH:


http://dash.iwh.on.ca/about-dash
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Appendix C
G-code Modifier Card
G-code Modifiers
CN (100 %) - 100
CM (80-99%) - 80-99
CL (60-79%) - 60 - 79
CK (40-59%) - 40-59
CJ (20-39%) - 20- 39
CI (1-19%) - 1-19
CH (0%) - 0
DASH SCORE
[(sum of n responses) - 1] x 25
n
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Appendix D
PowerPoint Content from In-Service Presentation
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Appendix E
Satisfaction Survey

Please circle the answer that best describes your feelings after this in-service presentation.
1. The information presented today was helpful for my clinical practice.
Strongly Agree

Agree

Neutral

Disagree

Strongly Disagree

2. I understand the different situations for which the DASH and the LLIS are recommended.
Strongly Agree

Agree

Neutral

Disagree

Strongly Disagree

3. I plan to use the DASH with the G-code modifier card in clinical practice.
Strongly Agree

Agree

Neutral

Disagree

Strongly Disagree

4. I feel more informed about current research around lymphedema HRQoL assessments after
this in-service.
Strongly Agree

Agree

Neutral

Disagree

Strongly Disagree

5. The research process, results, and conclusions were clearly and professionally presented.
Strongly Agree

Agree

Neutral

Disagree

Strongly Disagree

6. Was there any information that was not covered for which you would have liked to know more
about?
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
7. What barriers do you anticipate in implementing use of the LLIS or DASH?
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
8. Do you have any additional questions, comments, concerns, or suggestions related to this
research?
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
Thank you!
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Appendix F
Email to Sherri Olsen
Dear Sherri,
Thank you for your time in meeting with us today. We so enjoyed the opportunity to sit down and talk with you.
With regards to our discussion about getting G-code calculations for the DASH and LLIS into the Epic® EMR
system, here is what we recommend:
-For the LLIS, include a place in Epic® for the therapist to enter:
1. The final score (0-68)
2. The number of questions answered (0-17)
3. Question #18 regarding infection occurrence requiring oral antibiotics or hospitalization (options are 0-4 times)

4. Using the calculations in the attached Excel spreadsheet, have Epic® perform a calculation to convert the final
score and number of questions answered into a single correlating Medicare modifier to be inputted into the patient’s
record.
*This in effect creates a G-code calculator directly into Epic®, bypassing the Excel spreadsheet G-code calculator
that came attached with the LLIS.

For the DASH, include a place in Epic® for the therapist to enter:
1. The sum of responses (0-150)
2. The number of questions answered (n=0-30)
3. Have Epic® perform a calculation to convert the sum of responses and number of questions answered into a final
score using the formula below.
Formula:
DASH Disability/Symptom Score = [((sum of n responses)/n)-1] x 25, where n is equal to the number of completed
responses.
4. Then convert the final DASH disability score into a single correlating Medicare modifier to be inputted into the
patient’s record using the Medicare modifiers located in the attached Excel spreadsheet (e.g. 100% impairment (CN)
correlates with a score of 100, 80% impairment (CM) correlates with a score of 80, etc.).
5. Please provide a note for therapists: there must be at least 27 out of 30 responses answered to complete the
calculation.

Additionally, include a place for the therapist to enter the optional subtest scores for:
1. Work Module:
The sum of responses (0-20)
The number of questions answered (n=0-4)
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2. Sports/Performing Arts Module:
The sum of responses (0-20)
The number of questions answered (n=0-4)
For both of the optional modules, the final score is calculated with the formula below.
Disability Score = [((sum of responses)/4)-1] x 25, where n is equal to the number of completed responses.
*Please provide a note for therapists that all 4 of the optional responses must be answered to be calculated for each
subtest.

These calculations for both the LLIS and the DASH should be accessible for therapists to document in evaluation,
progress, and discharge reports.
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Table 1. Overview of HRQOL Assessments Analyzed
Type of assessment

Assessment

Lymph
Breast
Cancer
Generic
edema
Cancer

x

DASH

EORTC
QLQ BR23

FACT-B

FACT-B+4

FLIC

x

Areas Assessed

UE
Only
&
Categories/Subscales
UE
LE

x

Study

Clinical
Utility

TestRetest
Reliability

Intern
al
Consis
tency

Studi
ed in
the
U.S.?

Study
Populat
ion

Time
requi
red

Avail
able

EDGE
Task
Force
Rating
*

ICC=0.920.97

α=0.92
-0.97

Y

N=144

5-10
min.

Free

4

Not tested

α=0.46
-0.94

Y

Dutch=
70,
Spanish
=168,
U.S.=
158

Not
rated

x

Functional: body
image and sexuality –
Symptoms: arm,
breast, systemic
therapy side effects

ICC=0.85

α=0.62
-0.90

Y

N=47
N=295

5-10
min.

Free

Not
rated

x

Physical well-being –
Social/family wellbeing – Emotional
well-being –
Functional well-being
Physical well-being –
Social/family wellbeing – Emotional
well-being –
Functional well-being
– Arm morbidity

ICC=0.97

α=0.83
-0.88

N

N=279
N=29

5-10
min.

Free

4

Role – Sociability –
Emotional – Current
health – hardship –
Nausea – Pain

Not tested

α=0.90
-0.94

x

X

Social – Psychological
– Physical functioning
- Symptoms

Psychometrics

N=489

Not
rated
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LLIS

LymphICF

LymphICF-LL

x

Physical –
Psychosocial –
Functional concerns

ICC=0.940.98

α=0.93

Y

N=102

5-10
min.

Function: physical,
mental – Activity and
participation
limitations: household,
mobility, life domains/
social life

ICC=0.93

α=0.92

N

N=90

5
min.

2A

ICC=0.93

α=0.82
-0.97

N

N=50

5-10
min.

Not
rated

X

Function: physical,
mental – Activity and
participation
limitations: general
tasks/ household
activities, mobility,
life domains/ social
life

ICC=0.80

α=0.80
-0.89

N

X

Functional –
Appearance/bodyimage – Physical
symptoms –
Emotions/mood

U.K.=
209,
Dutch=
60

Physical –
Psychological – Social

ICC=0.700.86

α=0.78
-0.93

N

N=301
N=145

X

x

x

LYMQOL

x

ULL-27

x

x

x

*See Appendix A for EDGE Task Force Rating descriptions.
**Other assessments that were not included in the table due to insufficient psychometric data:
SF-36
LYQLI

Free

Not
rated

1

11
min.

2A
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Table 2: Tasks, Products, and Target Dates for Knowledge Translation
Task/Product
(1a-f above)

Deadline
Date

Steps w/ Dates to achieve the final outcome

1. Create G-code Calculator for
DASH

April 4
(Prior to meeting
with Sherri)





Research G-code criteria (March 2)
Develop excel calculation sheet (March 23)
Compare results with LLIS calculator (April
4)

2. Meet Independently with Sherri
Olsen

Prior to April
19th.




Email to set up meeting (March 15)
Meet with Heidi’s boss, Sherri to present our
research and new G-code calculator.
Advocate for having the calculator
programmed into their Epic® documentation
system.



3. In-service with MultiCare
Lymphedema Therapists

April 26th or
May 3rd






4. Submit to Nat’l Lymph. Network
and/or AOTA 2018 conference

TBD




Create a clinical reasoning guide for when to
use the LLIS or DASH
Visual aid (PowerPoint) on our findings
Satisfaction survey following presentation
(April 20)

Research requirements and deadlines for
application process (March 20)
Create an abstract of our research paper
(April 10)
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Table 3: Knowledge Translation Completion Timeline
Knowledge Translation Item

Target Date

Completion Date

Notes

G-code Calculator for the DASH
 Research G-code criteria
 Develop excel calculation
sheet
 Compare results with
LLIS

April 4, 2017
 March 2, 2017
 March 23, 2017
 April 4, 2017

March 26, 2017
 March 10,
2017
 N/A
 N/A

Created laminated G-code
modifier card for DASH in
replacement of a G-code
calculator.

Meet independently with Sherri
Olsen
 Email to set up meeting

April 19, 2017
 March 15, 2017

April 14, 2017
 March 6,
2017 &
March,
23, 2017

Follow up email with
directions to input
assessments into Epic®
delivered April 14, 2017.
Plans to remain in
communication via email in
regards to implementation
status.

In-service for MultiCare
Lymphedema Therapists
 Clinical reasoning guide
 PowerPoint on findings
 Satisfaction Survey

April 26/May 3, 2017
 April 20, 2017
 April 20, 2017
 April 20, 2017

March 29, 2017
 N/A
 March 26,
2017
 March 26,
2017

Submit to present at 2018
conferences (AOTA 2018, NLN
2019)
 Research requirements
 Create abstract

TBD



TBD


March 20, 2017
April 10, 2017



Clinician reasoning
delivered through oral
communication during inservice.

Submission guidelines
March 19, posted as of May 1, 2017
for AOTA 2018
2017
conference.
April 7,
2017
No data found regarding
National Lymphedema
conference.
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Permission for Scholarly Use of Thesis

To properly administer the Research Repository and preserve the contents for future use, the University of Puget
Sound requires certain permissions from the author(s) or copyright owner. By accepting this license, I still retain
copyright to my work. I do not give up the right to submit the work to publishers or other repositories. By accepting
this license, I grant to the University of Puget Sound the non-exclusive right to reproduce, translate (as defined below),
and/or distribute my submission (including the abstract) worldwide, in any format or medium for non-commercial,
academic purposes only. The University of Puget Sound will clearly identify my name(s) as the author(s) or owner(s)
of the submission, including a statement of my copyright, and will not make any alteration, other than as allowed by
this license, to my submission. I agree that the University of Puget Sound may, without changing the content, translate
the submission to any medium or format and keep more than one copy for the purposes of security, back up and
preservation. I also agree that authorized readers of my work have the right to use it for non-commercial, academic
purposes as defined by the "fair use" doctrine of U.S. copyright law, so long as all attributions and copyright
statements are retained. If the submission contains material for which I do not hold copyright and that exceeds fair use,
I represent that I have obtained the unrestricted permission of the copyright owner to grant the University of Puget
Sound the rights required by this license, and that such third-party owned material is clearly identified and
acknowledged within the text or content of the submission. I further understand that, if I submit my project for
publication and the publisher requires the transfer of copyright privileges, the University of Puget Sound will
relinquish copyright, and remove the project from its website if required by the publisher.
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